NASDAQ$IMNM
Immunome Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter and provided a corporate update.
Immunome reported its Q2 2022 financial results, highlighting its transition into a clinical-stage company with the ongoing Phase 1b study of IMM-BCP-01 and continued progress with its lead oncology candidate, IMM-ONC-01.
- Transitioned into a clinical stage company.
- Continued to dose patients in Phase 1b study of COVID-19 antibody cocktail, IMM-BCP-01.
- Presented data demonstrating retention of neutralizing activity against the BA.4/.5, and BA.2.12.1 subvariants of SARS CoV-2.
- Advanced IMM-ONC-01 towards IND submission.
Headline financials
Revenue & EPS history
Immunome · Revenue · Quarterly
$500K
Forward guidance
The press release includes forward-looking statements regarding Immunome’s beliefs and expectations regarding the advancement of its platform and programs, execution of its regulatory, research, clinical and strategic plans and anticipated upcoming milestones for its platform and programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
+0.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+24.1%
Q4 2021
Best reaction
-10.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.3% | -9.1% | -20.0% | |
| Q4 2025 | +4.7% | -1.0% | +1.4% | |
| Q3 2025 | -5.0% | +2.5% | +12.3% | |
| Q1 2025 | +1.1% | -1.0% | +15.0% | |
| Q4 2024 | -4.0% | -18.9% | -7.7% | |
| Q3 2024 | -10.8% | -24.5% | +0.7% | |
| Q2 2024 | +4.7% | +4.7% | +11.9% | |
| Q1 2024 | -1.3% | -6.2% | -3.2% | |
| Q4 2023 | -2.3% | -16.2% | -46.2% | |
| Q3 2023 | -8.1% | -8.9% | -12.2% | |
| Q2 2023 | -1.9% | -0.8% | +3.9% | |
| Q1 2023 | +2.3% | +11.9% | -6.2% | |
| Q4 2022 | +20.8% | +18.9% | +2.3% | |
| Q3 2022 | +0.0% | -27.6% | -8.5% | |
| Q2 2022 | +19.3% | +13.6% | +24.7% | |
| Q1 2022 | -2.6% | +19.6% | +46.5% | |
| Q4 2021 | +24.1% | +20.1% | -26.3% | |
| Q3 2021 | -1.0% | -5.1% | -9.3% | |
| Q2 2021 | -3.2% | -11.9% | +51.2% | |
| Q1 2021 | -10.7% | -3.0% | -2.9% | |
| Q4 2020 | -1.0% | -4.3% | -8.3% | |
| Q3 2020 | -5.5% | -6.4% | -6.1% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro